Premature ejaculation
diseaseOn this page
Also known as premature ejaculation (disease)
Summary
Premature ejaculation (MONDO:0001780) is a disease with 10 GWAS associations across 1 studies and 86 clinical trials. Top therapeutic interventions include paroxetine, sildenafil, and tadalafil. A subtype of sexual disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 10
- Clinical trials: 86
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | premature ejaculation |
| Mondo ID | MONDO:0001780 |
| MeSH | D061686 |
| DOID | DOID:13709 |
| ICD-10-CM | F52.4 |
| NCIT | C94349 |
| UMLS | C0033038 |
| MedGen | 452112 |
| Is cancer (heuristic) | no |
Also known as: premature ejaculation · premature ejaculation (disease)
Data availability: 10 GWAS associations (1 study) · 1 HPO phenotype.
Disease family
This is a subtype of sexual disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › sexual disorder › premature ejaculation
Related subtypes (3): psychosexual disorder, sexual sadism disorder, sexual masochism disorder
Genetics & variants
GWAS landscape
10 GWAS associations across 1 studies. Top hits map to 4 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs66508088 | 1e-06 | RNU1-45P - RNA5SP173 | ? | 0.48 |
| rs10114657 | 1e-06 | DELEC1 | ? | 2.42 |
| rs10120850 | 1e-06 | DELEC1 | ? | 2.42 |
| rs872111 | 2e-06 | SULF2 | ? | 0.42 |
| rs72668248 | 2e-06 | HNRNPA1P63 - ACOT11 | ? | 0.15 |
| rs77599229 | 2e-06 | HNRNPA1P63 - ACOT11 | ? | 0.15 |
| rs6825224 | 2e-06 | RPS3AP18 - TMEM154 | ? | 0.45 |
| rs2013948 | 3e-06 | LACTBL1 | ? | 2.11 |
| rs11818135 | 3e-06 | FAM53B | ? | 2.29 |
| rs9279036 | 4e-06 | HCG27 - HLA-C | ? | 2.1 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90102431 | Wang F | 2022 | 120 | 0 | Genome-Wide Association Analysis to Search for New Loci Associated with Lifelong Premature Ejaculation Risk in Chinese Male Han Population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 2 |
| Tier 4: intronic/intergenic | 8 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 10 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 5 |
| intergenic_variant | 2 |
| regulatory_region_variant | 2 |
| non_coding_transcript_exon_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs66508088 | 4 | 178337268 | C>T | 0.05 | intergenic_variant | RNU1-45P - RNA5SP173 | 1e-06 | Tier 4: intronic/intergenic |
| rs10114657 | 9 | 114967611 | A>C,G | 0.05 | intron_variant | DELEC1 | 1e-06 | Tier 4: intronic/intergenic |
| rs10120850 | 9 | 114967944 | C>A | 0.05 | intron_variant | DELEC1 | 1e-06 | Tier 4: intronic/intergenic |
| rs872111 | 20 | 47760434 | C>A,G,T | 0.05 | intron_variant | SULF2 | 2e-06 | Tier 4: intronic/intergenic |
| rs72668248 | 1 | 54542000 | A>G | 0.05 | regulatory_region_variant | HNRNPA1P63 - ACOT11 | 2e-06 | Tier 3: regulatory |
| rs77599229 | 1 | 54542068 | C>A,T | 0.05 | regulatory_region_variant | HNRNPA1P63 - ACOT11 | 2e-06 | Tier 3: regulatory |
| rs6825224 | 4 | 152613922 | A>G | 0.05 | non_coding_transcript_exon_variant | RPS3AP18 - TMEM154 | 2e-06 | Tier 4: intronic/intergenic |
| rs2013948 | 1 | 22960391 | A>G,T | 0.05 | intron_variant | LACTBL1 | 3e-06 | Tier 4: intronic/intergenic |
| rs11818135 | 10 | 124634655 | A>C | 0.05 | intron_variant | FAM53B | 3e-06 | Tier 4: intronic/intergenic |
| rs9279036 | 6 | 31229300 | GAAA>G,GA,GAA,GAAAA,GAAAAA | 0.05 | intergenic_variant | HCG27 - HLA-C | 4e-06 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 8 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Benzocaine | Approved (phase 4) |
| Lidocaine | Approved (phase 4) |
| Clomipramine | Phase 3 (in late-stage trials) |
| Cyanocobalamin | Phase 3 (in late-stage trials) |
| Dapoxetine | Phase 3 (in late-stage trials) |
| Folic Acid | Phase 3 (in late-stage trials) |
| Hyaluronic Acid | Phase 3 (in late-stage trials) |
| Paroxetine | Phase 3 (in late-stage trials) |
| Tadalafil | Phase 3 (in late-stage trials) |
| Tamsulosin | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Onabotulinumtoxina, Prilocaine, Sildenafil, Silodosin, Sodium Chloride.
Clinical trials & evidence
Clinical trials
Clinical trials: 86.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 43 |
| PHASE2 | 14 |
| PHASE3 | 13 |
| PHASE1 | 6 |
| PHASE4 | 4 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02939495 | PHASE4 | COMPLETED | The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy |
| NCT03177746 | PHASE4 | UNKNOWN | The Safety of Dapoxetine/Tadalafil Combination Therapy |
| NCT05183334 | PHASE4 | UNKNOWN | Combined On-demand Sildenafil Citrate and Tramadol Hydrochloride for Treatment of Premature Ejaculation |
| NCT07113145 | PHASE4 | COMPLETED | Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation |
| NCT05052879 | PHASE3 | NOT_YET_RECRUITING | Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation |
| NCT06425224 | PHASE3 | RECRUITING | Effectiveness and Safety of TENS Therapy for Premature Ejaculation |
| NCT06851598 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Safety and Efficacy of Botulinum Toxin-A Injection Into Ischiocavernosus Muscle for Premature Ejaculation |
| NCT00556478 | PHASE2/PHASE3 | COMPLETED | Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation |
| NCT00983151 | PHASE3 | TERMINATED | Study to Evaluate Efficacy and Safety in Males Subjects With Premature Ejaculation |
| NCT00983736 | PHASE3 | TERMINATED | Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation |
| NCT01024491 | PHASE3 | COMPLETED | Efficacy and Safety of Paroxetine Daily Doses of 15 mg and 20 mg in the Treatment of Premature Ejaculation |
| NCT01439984 | PHASE3 | COMPLETED | Trial of PED-1 in Male Patients With Premature Ejaculation |
| NCT02241460 | PHASE3 | UNKNOWN | Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation |
| NCT03459833 | PHASE3 | COMPLETED | Glans Penis Augmentation by Hyaluronic Acid for Treatment of Premature Ejaculation |
| NCT03629769 | PHASE3 | UNKNOWN | Effects of Proxelan Somministration in Patients With Chronic Prostatitis |
| NCT03879746 | PHASE3 | UNKNOWN | Effect of Tamsulosin on PE Compared With Paroxetine Hydrochloride |
| NCT04085354 | PHASE3 | COMPLETED | Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation |
| NCT04361305 | PHASE3 | UNKNOWN | Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction |
| NCT04703127 | PHASE3 | UNKNOWN | Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone. |
| NCT07081659 | PHASE2/PHASE3 | COMPLETED | On-demand Silodosin 4mg vs Dapoxetine 60mg in Treatment of Primary Premature Ejaculation |
| NCT07047404 | PHASE2 | RECRUITING | Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation |
| NCT07434271 | PHASE2 | RECRUITING | Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE) |
| NCT00370981 | PHASE2 | COMPLETED | Exploratory Study of Pagoclone in Men With Premature Ejaculation. |
| NCT00537459 | PHASE2 | COMPLETED | A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation |
| NCT01021553 | PHASE2 | COMPLETED | A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation |
| NCT01203202 | PHASE2 | COMPLETED | Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation |
| NCT01419470 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044 |
| NCT01798667 | PHASE2 | UNKNOWN | Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation |
| NCT01917006 | PHASE2 | TERMINATED | A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation |
| NCT02232425 | PHASE2 | COMPLETED | IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE) |
| NCT02571101 | PHASE2 | UNKNOWN | A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation |
| NCT02581826 | PHASE2 | UNKNOWN | Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation |
| NCT03055806 | PHASE2 | COMPLETED | IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE) |
| NCT03578783 | PHASE2 | COMPLETED | PSD502 in Subjects With Premature Ejaculation |
| NCT04850703 | PHASE1/PHASE2 | COMPLETED | Brain Networks Implicated in Lifelong Premature Ejaculation Patients |
| NCT05556083 | PHASE2 | UNKNOWN | Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE) |
| NCT00449709 | PHASE1 | TERMINATED | A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects |
| NCT00549211 | PHASE1 | COMPLETED | A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296. |
| NCT00664365 | PHASE1 | COMPLETED | FTIH Study With GSK958108 |
| NCT00861484 | PHASE1 | COMPLETED | Proof of Mechanism in ELT |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PAROXETINE | 4 | 4 |
| SILDENAFIL | 4 | 3 |
| TADALAFIL | 4 | 3 |
| TAMSULOSIN | 4 | 3 |
| TRAMADOL | 4 | 3 |
| CLOMIPRAMINE | 4 | 2 |
| CYANOCOBALAMIN | 4 | 2 |
| HYALURONIC ACID | 4 | 1 |
| ONABOTULINUMTOXINA | 4 | 1 |
| PRILOCAINE | 4 | 1 |
| SILODOSIN | 4 | 1 |
| DAPOXETINE | 3 | 8 |
| RETOSIBAN | 3 | 1 |
| EPELSIBAN | 2 | 2 |
| BP-14979 | 2 | 1 |
| DA-8031 | 2 | 1 |
| PAGOCLONE | 2 | 1 |
| GSK-958108 | 1 | 2 |
| CHEMBL139521 | 0 | 3 |
| CHEMBL177542 | 0 | 3 |
| CHEMBL4244897 | 0 | 3 |
| (R,R)-TRAMADOL | 0 | 3 |
| CHEMBL4059722 | 0 | 2 |
| CHEMBL4303681 | 0 | 2 |
| VITAMIN B12 | 0 | 2 |